reason report
solid improv execut drive om expans
bottom line deliv solid beat continu
weak cvg cardiac vascular group off-set strength
segment even cvg deliv bright spot within busi
growth less bad fear dcb drug coat balloon sale
quarter ep beat vs street provid earli
indic manag recent initi focu higher-
margin pipelin product tie oper margin compens
busi unit head seem deliv dividend abil
drive consist oper margin expans one key
stick point us relat mp rate share
still earli day admit sale growth oper
margin expans exceed street estim
manag reiter organ sale guidanc
rais ep commentari post-
earn call highlight manag confid growth acceler
comp get easier key product launch start
contribut current trade discount broader med-tech
group -- vs group believ
multipl expans hing upon pipelin execut
sale growth trajectori highli lever success execut
current upcom new product launch across wide rang
products/busi notabl gener surgeri robot
manag discuss upcom analyst event hartford
ct consist sign sustain posit oper margin
expans driver build confid manag project
 per year inclin take conserv stanc
need convict behind pipelin execut consist
margin expans believ could repres rel safe
invest continu volatil market
reiter mp pt -- -- price
target appli price-to-earnings multipl ep estim
assum share sustain current multipl
ep estim though believ could eventu
return path consist mid-single-digit top-lin growth time
less certain see limit multipl expans
mid-single-digit growth trajectori larg predic new
product launch sustain trend without risk
outlook estim move higher reflect
ep guidanc rais estim sale y/i
oper report ep report
compani inform svb leerink llc research
revenu mm ep
medic suppli devic
ep
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
rate share market perform price target believ
return mid-single-digit top-lin growth trajectori eventu nearli total
sale cardiac rhythm manag spine market estim grow
low-single-digit best mdt sustain growth trajectori larg predic
recent upcom new product launch well success integr covidien
largest acquisit compani histori
ceo omar ishrak helm clearli focus control cost help off-set
on-going price pressur slow market growth broadli med-tech excis tax
name see opportun margin expans combin compani
attempt extract signific cost synergi though compani continu make progress
time extent margin improv still remain challeng increas fx pressur
despit earli sign market stabil market growth recoveri coupl
continu soft spine inclin remain sidelin share
pend clariti execut upcom new product launch help stem
market share loss spine drive market share gain busi
success deliv increment margin expans beyond cov synergi
major med-tech market broadli spine specif experienc real
price target appli price-to-earnings multipl ep estim
assum share sustain current multipl ep estim
though believ could eventu return path consist mid-
single-digit top-lin growth -- rtg big piec growth acceler -- remain
sidelin pend clariti cvg sale abil absorb/mov
past on-going headwind ramp key pipelin product surgic robot
minim invas therapi group mitg time less certain see limit multipl
expans mid-single-digit growth trajectori larg predic new
product launch sustain trend without risk
risk valuat includ continu signific spine market spine sale declin
market fail regain momentum greater-than-expect drug elut stent de market
share loss greater infus sale declin failur deliv product pipelin failur
success execut cost save initi
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item includ contributor visibl alpha
consensu estim
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item includ contributor visibl alpha
consensu estim
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom continu oper
earn discontinu oper net tax
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
revenu report
oper revenu ex fx divestitur
compani report svb leerink estim
sg
lower end
op margin
similar
similar
op margin
impli
ep growth
ex fx fx impact
impli
ep growth
ex fx fx impact
low- mid-teen
similar
impact neg
impact neg
impact neg
impact neg
fx impact neg
impli base
higher end
organ ex fx impact
neg fx impact
higher end
organ ex fx impact
neg fx impact
low- mid-teen
low- mid-teen
stronger
littl
impact neg
posit fx impact
closer
minu side
full year
stronger
stronger
improv
mid high singl
mid high singl
minu side
full year
impact fx
impact fx
impli
ep growth
ex fx fx impact
neutral
impli
ep growth
ex fx fx impact
fx
impli
ep growth
midpoint ex fx
impact
fx
greater
save
ex fx
ex fx
greater
save
ex fx
sg increas
fx posit
greater
save
ex fx
lower half mid-singl
fx
headwind
lower half mid-singl
impact fx
sg increas
flat fx
flat
ex fx
upper end singl digit
rang fx
renal nerv denerv patient hypertens paroxysm
persist atrial fibril purpos clinic studi evalu
feasibl perform renal nerv denerv pulmonari vein isol
patient intent character safeti effect
paroxysm persist atrial fibril popul hypertens assess
safeti studi measur occurr composit safeti endpoint
assess effect studi measur freedom chronic treatment failur
minimum six month follow-up
replac
studi object demonstr safeti effect
medtron tavr system measur rate all-caus mortal disabl
stroke two year noninferior savr treatment sever aortic stenosi
subject low predict risk oper mortal savr
global clinic studi renal denerv symplic spyral multi-
electrod renal denerv system patient uncontrol hypertens
absenc antihypertens medic
purpos studi obtain assess efficaci safeti
renal denerv absenc antihypertens medic
global clinic studi renal denerv symplic spyral multi-
electrod renal denerv system patient uncontrol hypertens
purpos studi obtain assess efficaci safeti
renal denerv presenc three standard antihypertens medic
spyral htn pivot trial part broader spyral htn global clinic
program multi-phas clinic studi strategi aim establish safeti
efficaci renal denerv lower blood pressur trial investig
blood pressur lower effect safeti renal denerv absenc
medic primari efficaci safeti endpoint trial blood
pressur three month incid major advers event one-month
particip random corevalve/evolut savr
earli data patient present european societi cardiolog
esc investig found statist signific
clinic import blood pressur reduct patient treat
renal denerv across offic ambulatori systol
earli data first patient enrol prospect
random sham-control spyral htn-on trial present
late-break clinic trial session europcr meet
commenc may pari franc
receiv fda approv begin pivot trial
spyral htn pivot trial random sham-control studi
investig renal denerv procedur patient
site europ australia japan
stand alon cgm system guardian connect launch sugar iq
adult pediatr
purpos studi evalu safeti effect hybrid
close loop system hcl adult pediatr patient type diabet
home set divers popul patient type diabet
advanc hybrid close loop system bluetooth
new cgm system type
plan enrol patient
